Teva Pharmaceutical/$TEVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Teva Pharmaceutical
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ticker
$TEVA
Sector
Primary listing
NYSE
Employees
37,000
Headquarters
Tel Aviv, Israel
Website
TEVA Metrics
BasicAdvanced
$23B
-
-$0.14
0.73
-
Price and volume
Market cap
$23B
Beta
0.73
52-week high
$22.80
52-week low
$12.47
Average daily volume
10M
Financial strength
Current ratio
1.064
Quick ratio
0.483
Long term debt to equity
249.62
Total debt to equity
256.687
Interest coverage (TTM)
3.59%
Profitability
EBITDA (TTM)
4,522
Gross margin (TTM)
49.60%
Net profit margin (TTM)
-0.94%
Operating margin (TTM)
22.16%
Effective tax rate (TTM)
-138.24%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.37%
Return on equity (TTM)
-2.42%
Valuation
Price to revenue (TTM)
1.369
Price to book
3.36
Price to tangible book (TTM)
-1.73
Price to free cash flow (TTM)
25.586
Free cash flow yield (TTM)
3.91%
Free cash flow per share (TTM)
0.782
Growth
Revenue change (TTM)
2.07%
Earnings per share change (TTM)
-65.07%
3-year revenue growth (CAGR)
2.52%
10-year revenue growth (CAGR)
-1.91%
3-year earnings per share growth (CAGR)
-47.14%
10-year earnings per share growth (CAGR)
-26.26%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Bulls say / Bears say
Teva’s Q2 2025 adjusted EPS reached $0.66, beating consensus of $0.62, supported by 26% growth in branded drugs including Austedo, Ajovy, and Uzedy (Reuters)
The company increased its 2025 EPS guidance to $2.50–$2.65 and maintained its revenue forecast at $16.8–$17.2 billion, showing confidence in its financial prospects (Reuters)
Teva anticipates its upcoming launch pipeline—including its schizophrenia drug Olanzapine set for Q4—to potentially peak at over $10 billion in sales, supporting its long-term growth outlook (Reuters)
Global generic drug sales remained flat in Q2 2025, with U.S. volumes falling due to continued pricing pressure in Teva’s core business (Reuters)
Q2 2025 revenue came in at $4.18 billion, below analyst expectations of $4.28 billion, raising concerns about revenue growth (Reuters)
There is uncertainty regarding the potential impact of U.S. import tariffs on pharmaceuticals, creating questions around future costs and profit margins (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
TEVA News
AllArticlesVideos
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
Business Wire3 weeks ago
Colorado must face Teva's lawsuit over free allergy pen law
Reuters1 month ago
US FDA approves Teva Pharmaceuticals' generic obesity drug
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Teva Pharmaceutical stock?
Teva Pharmaceutical (TEVA) has a market cap of $23B as of October 07, 2025.
What is the P/E ratio for Teva Pharmaceutical stock?
The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of October 07, 2025.
Does Teva Pharmaceutical stock pay dividends?
No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Teva Pharmaceutical dividend payment date?
Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Teva Pharmaceutical?
Teva Pharmaceutical (TEVA) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.